Forskningsresultat per år
Forskningsresultat per år
- 8 resultat
Sökresultat
-
2019
Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling
Murumagi, A., Ungureanu, D., Khan, S., Hirasawa, A., Arjama, M., Valimaki, K., Mikkonen, P., Niininen, W., Kumar, A., Eldfors, S., Pellinen, T., Pietiainen, V., Magi, A., Koivisto-Korander, R., Tapper, J., Loukovaara, M., Aittokallio, T., Butzow, R. & Kallioniemi, O., juli 2019, I: Cancer Research. 79, 13, 2 s.Forskningsoutput: Tidskriftsbidrag › Mötesabstrakt › Peer review
-
2018
Precision cancer medicine based on 3D drug profiling of patient-derived cancer cell spheroid models
Mikkonen, P., Turunen, L., Paasonen, L., Potdar, S., Paavolainen, L., Murumagi, A., Kallioniemi, O. & Pietiainen, V. M., juli 2018, I: Cancer Research. 78, 13, 2 s.Forskningsoutput: Tidskriftsbidrag › Mötesabstrakt › Peer review
-
2017
Identifying ovarian cancer specific targeted drugs using high-throughput drug sensitivity profiles of primary cancer cells
Murumagi, A., Hirasawa, A., Khan, S., Ungureanu, D., Arjama, M., Pellinen, T., Eldfors, S., Koivisto-Korander, R., Leminen, A., Butzow, R., Aittokallio, T. & Kallioniemi, O., juli 2017, I: Cancer Research. 77, Supplement 13, 2 s., 410.Forskningsoutput: Tidskriftsbidrag › Mötesabstrakt › Peer review
-
Pharmacogenomic profiling to identify novel therapeutic strategies in colorectal cancer
Bruun, J., Eide, P. W., Kryeziu, K., Sveen, A., Murumagi, A., Kolberg, M., Arjama, M., Kallioniemi, O. & Lothe, R. A., juli 2017, I: Cancer Research. 77, 2 s.Forskningsoutput: Tidskriftsbidrag › Mötesabstrakt › Peer review
-
2016
Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells
Murumagi, A., Hirasawa, A., Khan, S., Arjama, M., Pellinen, T., Koivisto-Korander, R., Leminen, A., Magi, A., Aittokallio, T., Butzow, R. & Kallioniemi, O., okt. 2016, I: International Journal of Gynecological Cancer. 26, s. 653-653 1 s.Forskningsoutput: Tidskriftsbidrag › Mötesabstrakt › Peer review
-
2015
High-throughput drug sensitivity and resistance testing of ovarian cancer cell lines provides useful strategy for assessing drug repositioning and therapeutic possibilities of emerging drugs
Hirasawa, A., Murumagi, A., Arjama, M., Yadav, B., Mpindi, J. P., Wennerberg, K., Aittokallio, T., Aoki, D. & Kallioniemi, O., 15 aug. 2015, I: Clinical Cancer Research. 21, 1 s.Forskningsoutput: Tidskriftsbidrag › Mötesabstrakt › Peer review
-
2014
Systematic high-throughput drug sensitivity and resistance testing (DSRT) of ovarian cancer cell lines indicates novel therapeutic possibilities with existing and emerging drugs
Hirasawa, A., Murumagi, A., Arjama, M., Yadav, B., Mpindi, J. P., Wennerberg, K., Aittokallio, T., Aoki, D. & Kallioniemi, O., 1 okt. 2014, I: Cancer Research. 74, 19, 1 s.Forskningsoutput: Tidskriftsbidrag › Mötesabstrakt › Peer review
-
2012
High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML
Heckman, C. A., Kontro, M., Pemovska, T., Eldfors, S., Edgren, H., Kulesskiy, E., Majumder, M. M., Karjalainen, R., Yadav, B., Szwajda, A., Venkata, N. P. K., Murumagi, A., Malani, D., Parsons, A., Hintsanen, P., Almusa, H., Marti, J. M. L., Ellonen, P., Mattila, P. & Lepisto, M. & 8 andra, , 16 nov. 2012, I: Blood. 120, 21, 2 s., Meeting Abstract: 288 .Forskningsoutput: Tidskriftsbidrag › Mötesabstrakt › Peer review